Project Grant R03CA283104
Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97213, USA
Similar Awards
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will provide real-time information on the endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma (MM) undergoing bispecific T-cell engager antibody (BiTEA) treatment. The goal is to better understand T-cell engagement and trafficking...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...
- This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...
- This Project Grant award, valued at $684,107 and funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to integrate circulating tumor cell and nuclear imaging biomarkers to assess the response and resistance to Lutetium-177-PSMA (LUPSMA) radiopharmaceutical therapy in advanced prostate cancer patients. The award was granted to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a renowned...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $149,394 to the University of California, Davis to support research on the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. The principal investigator has over 20 years of experience in designing, synthesizing, and optimizing radiopharmaceuticals targeting cancer cell-surface receptors for positron emission tomography (PET) imaging and...
- This $358,605 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support a pilot study at the University of Texas MD Anderson Cancer Center. The study aims to correlate PET/CT imaging using the novel radiotracer 4-[18F]fluoro-1-naphthol ([18F]4FN) with manifestations of chronic graft-versus-host disease in patients who have undergone allogeneic hematopoietic cell transplantation. The research will assess if [18F]4FN PET/CT can...
- This $597,766 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support the development of novel methods to image two different PET tracers concurrently in a single imaging session using a whole-body PET scanner. The research aims to improve the ability to non-invasively characterize tumor biology and guide precision medicine by enabling the simultaneous use of multiple PET tracers. Key activities include developing protocols to...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...